Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 4, 2009, Pages 457.e1-457.e5

  Huang, Gloria S ^a   Arend, Rebecca C ^a   Li, Maomi ^b   Gunter, Marc J ^a   Chiu, Lydia G ^a   Horwitz, Susan Band ^a   Goldberg, Gary L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

carcinosarcoma; estrogen receptor; growth factor receptor; progesterone receptor; uterine neoplasm

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA UROGASTRONE; PROGESTERONE RECEPTOR; RALOXIFENE; SOMATOMEDIN RECEPTOR; TAMOXIFEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; ENDOMETRIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RANK SUM TEST; TISSUE MICROARRAY; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 62549137808     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.12.012     Document Type: Article

References (33)

1. Silverberg S.G., Major F.J., Blessing J.A., et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9 (1990) 1-19
2. Bitterman P., Chun B., and Kurman R.J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathologic and immunohistochemical study. Am J Surg Pathol 14 (1990) 317-328
3. Amant F., Cadron I., Fuso L., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 98 (2005) 274-280
4. de Brito P.A., Silverberg S.G., and Orenstein J.M. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 24 (1993) 132-142
5. Gorai I., Yanagibashi T., Taki A., et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 72 (1997) 821-827
6. Iwasa Y., Haga H., Konishi I., et al. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 82 (1998) 512-519
7. Watanabe M., Shimizu K., Kato H., et al. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol Oncol 82 (2001) 563-567
8. McCluggage W.G. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12 (2002) 687-690
9. Amant F., Vloeberghs V., Woestenborghs H., et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 95 (2004) 583-587
10. Livasy C.A., Reading F.C., Moore D.T., Boggess J.F., and Lininger R.A. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100 (2006) 101-106
11. Rice L.W., Stone R.L., Xu M., et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mullerian tumors. Am J Obstet Gynecol 194 (2006) 1119-1126 discussion 1126-8
12. Hubalek M., Ramoni A., Mueller-Holzner E., and Marth C. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Gynecol Oncol 95 (2004) 264-266
13. Deligdisch L., Kalir T., Cohen C.J., de Latour M., Le Bouedec G., and Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78 (2000) 181-186
14. Evans M.J., Langlois N.E., Kitchener H.C., and Miller I.D. Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?. Int J Gynecol Cancer 5 (1995) 310-313
15. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94 (2004) 256-266
16. Swerdlow A.J., and Jones M.E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97 (2005) 375-384
17. McCluggage W.G., Abdulkader M., Price J.H., et al. Uterine carcinosarcomas in patients receiving tamoxifen: a report of 19 cases. Int J Gynecol Cancer 10 (2000) 280-284
18. Goldman N.A., de Los Angeles M.M., Jones J.G., and Goldberg G.L. Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstet Gynecol 105 (2005) 1278-1280
19. Pelletier G., and El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 85 (2000) 4835-4840
20. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6 (2006) 360-368
21. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
22. Girault I., Lerebours F., Amarir S., et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9 (2003) 1259-1266
23. Song R.X., Zhang Z., Chen Y., Bao Y., and Santen R.J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148 (2007) 4091-4101
24. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
25. Huang G.S., Chiu L.G., Gebb J.S., et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 107 (2007) 513-517
26. Jazaeri A.A., Nunes K.J., Dalton M.S., Xu M., Shupnik M.A., and Rice L.W. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20 (2001) 6965-6969
27. Zafrakas M., Kostopoulou E., Dragoumis K., Mikos T., Papadimas J., and Bontis J. Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy: report of two cases. Eur J Gynaecol Oncol 25 (2004) 530-533
28. McCampbell A.S., Broaddus R.R., Loose D.S., and Davies P.J. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 12 (2006) 6373-6378
29. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., and Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26 (2005) 465-478
30. Cimbaluk D., Rotmensch J., Scudiere J., Gown A., and Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 105 (2007) 138-144
31. Massarweh S., Osborne C.K., Creighton C.J., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68 (2008) 826-833
32. Gunter M.J., Hoover D.R., Yu H., et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17 (2008) 921-929
33. Schulten H.J., Wolf-Salgo J., Grundker C., Gunawan B., and Fuzesi L. Characterization of a newly established uterine carcinosarcoma cell line featuring the sarcomatous phenotype of the tumor in vitro. Int J Gynecol Cancer 18 (2008) 339-344